Identification

Name
Methamphetamine
Accession Number
DB01577
Type
Small Molecule
Groups
Approved, Illicit
Description

Methamphetamine is a psychostimulant and sympathomimetic drug. It is a member of the amphetamine group of sympathomimetic amines. Methamphetamine can induce effects such as euphoria, increased alertness and energy, and enhanced self-esteem. It is a scheduled drug in most countries due to its high potential for addiction and abuse.

Structure
Thumb
Synonyms
  • (+)-(S)-N-alpha-Dimethylphenethylamine
  • (+)-(S)-N-α-dimethylphenethylamine
  • (AlphaS)-N,alpha-dimethylbenzeneethanamine
  • (S)-N,alpha-Dimethylbenzeneethanamine
  • (S)-N,α-dimethylbenzeneethanamine
  • (αS)-N,α-dimethylbenzeneethanamine
  • d-1-phenyl-2-methylaminopropane
  • d-deoxyephedrine
  • d-desoxyephedrine
  • d-N-methylamphetamine
  • d-phenylisopropylmethylamine
  • Dextromethamphetamine
  • Métamfétamine
  • Metamfetamine
  • Metamfetaminum
  • Metanfetamina
  • Methamphetamine
  • Methamphetaminum
  • Methyl-beta-phenylisopropylamine
  • methyl-β-phenylisopropylamine
External IDs
J6.362B / NSC-25115
Product Ingredients
IngredientUNIICASInChI Key
Methamphetamine hydrochloride997F43Z9CV51-57-0MYWUZJCMWCOHBA-VIFPVBQESA-N
Methamphetamine tartrate7520HJS99O62265-33-2SOSGXQJCXKXQCB-NDAAPVSOSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DesoxynTablet5 mg/1OralRecordati Rare Diseases Inc1943-12-312017-08-19Us
DesoxynTablet5 mg/1OralRecordati Rare Diseases Inc1943-12-31Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Methamphetamine HydrochlorideTablet5 mg/1OralMylan Pharmaceuticals2010-04-26Not applicableUs
Methamphetamine HydrochlorideTablet5 mg/1OralWest Ward Pharmaceutical2016-12-06Not applicableUs
Methamphetamine HydrochlorideTablet5 mg/1OralMayne Pharma2010-04-26Not applicableUs
Categories
UNII
44RAL3456C
CAS number
537-46-2
Weight
Average: 149.2328
Monoisotopic: 149.120449485
Chemical Formula
C10H15N
InChI Key
MYWUZJCMWCOHBA-VIFPVBQESA-N
InChI
InChI=1S/C10H15N/c1-9(11-2)8-10-6-4-3-5-7-10/h3-7,9,11H,8H2,1-2H3/t9-/m0/s1
IUPAC Name
methyl[(2S)-1-phenylpropan-2-yl]amine
SMILES
CN[[email protected]@H](C)CC1=CC=CC=C1

Pharmacology

Indication

For the treatment of Attention Deficit Disorder with Hyperactivity (ADHD) and exogenous obesity.

Structured Indications
Pharmacodynamics

Methamphetamine is a potent central nervous system stimulant which affects neurochemical mechanisms responsible for regulating heart rate, body temperature, blood pressure, appetite, attention, mood and responses associated with alertness or alarm conditions. The acute effects of the drug closely resemble the physiological and psychological effects of an epinephrine-provoked fight-or-flight response, including increased heart rate and blood pressure, vasoconstriction (constriction of the arterial walls), bronchodilation, and hyperglycemia (increased blood sugar). Users experience an increase in focus, increased mental alertness, and the elimination of fatigue, as well as a decrease in appetite.

Mechanism of action

Methamphetamine enters the brain and triggers a cascading release of norepinephrine, dopamine and serotonin. To a lesser extent methamphetamine acts as a dopaminergic and adrenergic reuptake inhibitor and in high concentrations as a monamine oxidase inhibitor (MAOI). The mechanism of action involved in producing the beneficial behavioral changes seen in hyperkinetic children receiving methamphetamine is unknown.

TargetActionsOrganism
ASodium-dependent dopamine transporter
negative modulator
Human
ASodium-dependent serotonin transporter
negative modulator
Human
ASodium-dependent noradrenaline transporter
negative modulator
Human
ASynaptic vesicular amine transporter
inhibitor
Human
AChromaffin granule amine transporter
inhibitor
Human
ATrace amine-associated receptor 1
agonist
Human
AAlpha-2A adrenergic receptor
agonist
Human
AAlpha-2B adrenergic receptor
agonist
Human
AAlpha-2C adrenergic receptor
agonist
Human
AAmine oxidase [flavin-containing] A
inhibitor
Human
AAmine oxidase [flavin-containing] B
inhibitor
Human
Absorption

Methamphetamine is rapidly absorbed from the gastrointestinal tract with peak methamphetamine concentrations occurring in 3.13 to 6.3 hours post ingestion. Methamphetamine is also well absorbed following inhalation and following intranasal administration. It is distributed to most parts of the body. Because methamphetamine has a high lipophilicity it is distributed across the blood brain barrier and crosses the placenta.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Hepatic. The primary site of metabolism is in the liver by aromatic hydroxylation, N-dealkylation and deamination. At least seven metabolites have been identified in the urine, with the main metabolites being amphetamine (active) and 4-hydroxymethamphetamine. Other minor metabolites include 4-hydroxyamphetamine, norephedrine, and 4-hydroxynorephedrine.

Route of elimination

Excretion occurs primarily in the urine, the rate of which is dependent on urine pH. Between 30-54% of an oral dose is excreted in urine as unchanged methamphetamine and 10-23% as unchanged amphetamine. Following an intravenous dose, 45% is excreted as unchanged parent drug and 7% amphetamine.

Half life

The biological half-life has been reported in the range of 4 to 5 hours.

Clearance
Not Available
Toxicity

Manifestations of acute overdosage with methamphetamine include restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, panic states, hyperpyrexia, and rhabdomyolysis. Fatigue and depression usually follow the central stimulation. Cardiovascular effects include arrhythmias, hypertension or hypotension, and circulatory collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea, and abdominal cramps. Fatal poisoning usually terminates in convulsions and coma.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
PRKCA-binding protein---(T;T) / (A;T) / (G;G) / (G;T)T allele / G alleleADR Directly StudiedThe prescence of this polymorphism in PICK1 is associated with increased susceptibility to drug-related psychosis and addiction when using methamphetamine.Details

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Methamphetamine.Experimental
AbirateroneThe serum concentration of Methamphetamine can be increased when it is combined with Abiraterone.Approved
AcebutololMethamphetamine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
AcepromazineAcepromazine may decrease the stimulatory activities of Methamphetamine.Approved, Vet Approved
AceprometazineAceprometazine may decrease the stimulatory activities of Methamphetamine.Approved
AcetazolamideAcetazolamide may decrease the excretion rate of Methamphetamine which could result in a higher serum level.Approved, Vet Approved
AcetophenazineAcetophenazine may decrease the stimulatory activities of Methamphetamine.Approved
AcrivastineMethamphetamine may decrease the sedative activities of Acrivastine.Approved
AlcaftadineMethamphetamine may decrease the sedative activities of Alcaftadine.Approved
AlfentanilMethamphetamine may increase the analgesic activities of Alfentanil.Approved, Illicit
AlgeldrateAlgeldrate may decrease the excretion rate of Methamphetamine which could result in a higher serum level.Experimental
AlimemazineMethamphetamine may decrease the sedative activities of Alimemazine.Approved, Vet Approved
AlmagateAlmagate may decrease the excretion rate of Methamphetamine which could result in a higher serum level.Experimental
AlmasilateAlmasilate may decrease the excretion rate of Methamphetamine which could result in a higher serum level.Experimental
AloglutamolAloglutamol may decrease the excretion rate of Methamphetamine which could result in a higher serum level.Experimental
AlphacetylmethadolMethamphetamine may increase the analgesic activities of Alphacetylmethadol.Experimental, Illicit
AlphaprodineMethamphetamine may increase the analgesic activities of Alphaprodine.Illicit
AlprenololMethamphetamine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Withdrawn
AluminiumAluminium may decrease the excretion rate of Methamphetamine which could result in a higher serum level.Approved
Aluminium acetoacetateAluminium acetoacetate may decrease the excretion rate of Methamphetamine which could result in a higher serum level.Experimental
Aluminium glycinateAluminium glycinate may decrease the excretion rate of Methamphetamine which could result in a higher serum level.Experimental
Aluminum hydroxideAluminum hydroxide may decrease the excretion rate of Methamphetamine which could result in a higher serum level.Approved
AmineptineAmineptine may decrease the antihypertensive activities of Methamphetamine.Illicit, Withdrawn
AmiodaroneThe metabolism of Methamphetamine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideAmisulpride may decrease the stimulatory activities of Methamphetamine.Approved, Investigational
AmitriptylineAmitriptyline may decrease the antihypertensive activities of Methamphetamine.Approved
Ammonium chlorideThe serum concentration of Methamphetamine can be decreased when it is combined with Ammonium chloride.Approved, Vet Approved
AmperozideAmperozide may decrease the stimulatory activities of Methamphetamine.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Methamphetamine.Approved, Illicit
AntazolineMethamphetamine may decrease the sedative activities of Antazoline.Approved
AripiprazoleAripiprazole may decrease the stimulatory activities of Methamphetamine.Approved, Investigational
ArotinololMethamphetamine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
ArtemetherThe metabolism of Methamphetamine can be decreased when combined with Artemether.Approved
AsenapineAsenapine may decrease the stimulatory activities of Methamphetamine.Approved
AstemizoleMethamphetamine may decrease the sedative activities of Astemizole.Approved, Withdrawn
AtenololMethamphetamine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
AtomoxetineAtomoxetine may increase the hypertensive activities of Methamphetamine.Approved
AzaperoneAzaperone may decrease the stimulatory activities of Methamphetamine.Vet Approved
AzatadineMethamphetamine may decrease the sedative activities of Azatadine.Approved
AzelastineMethamphetamine may decrease the sedative activities of Azelastine.Approved
BamipineMethamphetamine may decrease the sedative activities of Bamipine.Experimental
BefunololMethamphetamine may increase the atrioventricular blocking (AV block) activities of Befunolol.Experimental
BenmoxinBenmoxin may increase the hypertensive activities of Methamphetamine.Withdrawn
BenperidolBenperidol may decrease the stimulatory activities of Methamphetamine.Investigational
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Methamphetamine.Approved, Illicit
BetaxololMethamphetamine may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved
BevantololMethamphetamine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
BezitramideMethamphetamine may increase the analgesic activities of Bezitramide.Experimental, Illicit, Withdrawn
BifeprunoxBifeprunox may decrease the stimulatory activities of Methamphetamine.Investigational
Bismuth SubcitrateBismuth Subcitrate may decrease the excretion rate of Methamphetamine which could result in a higher serum level.Approved
Bismuth subnitrateBismuth subnitrate may decrease the excretion rate of Methamphetamine which could result in a higher serum level.Experimental
BisoprololMethamphetamine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
BopindololMethamphetamine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
BrexpiprazoleBrexpiprazole may decrease the stimulatory activities of Methamphetamine.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Brofaromine.Experimental
BromperidolBromperidol may decrease the stimulatory activities of Methamphetamine.Investigational
BrompheniramineMethamphetamine may decrease the sedative activities of Brompheniramine.Approved
BucindololMethamphetamine may increase the atrioventricular blocking (AV block) activities of Bucindolol.Investigational
BuclizineMethamphetamine may decrease the sedative activities of Buclizine.Approved
BufuralolMethamphetamine may increase the atrioventricular blocking (AV block) activities of Bufuralol.Experimental, Investigational
BupranololMethamphetamine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
BuprenorphineMethamphetamine may increase the analgesic activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Methamphetamine can be decreased when combined with Bupropion.Approved
ButaperazineButaperazine may decrease the stimulatory activities of Methamphetamine.Experimental
ButorphanolMethamphetamine may increase the analgesic activities of Butorphanol.Approved, Illicit, Vet Approved
Butyric AcidMethamphetamine may decrease the sedative activities of Butyric Acid.Experimental
Calcium CarbonateCalcium Carbonate may decrease the excretion rate of Methamphetamine which could result in a higher serum level.Approved
Calcium silicateCalcium silicate may decrease the excretion rate of Methamphetamine which could result in a higher serum level.Experimental
CarbinoxamineMethamphetamine may decrease the sedative activities of Carbinoxamine.Approved
CarfentanilMethamphetamine may increase the analgesic activities of Carfentanil.Illicit, Vet Approved
CariprazineCariprazine may decrease the stimulatory activities of Methamphetamine.Approved
CaroxazoneCaroxazone may increase the hypertensive activities of Methamphetamine.Withdrawn
CarteololMethamphetamine may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved
CarvedilolMethamphetamine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Investigational
CelecoxibThe metabolism of Methamphetamine can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololMethamphetamine may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved, Investigational
CetirizineMethamphetamine may decrease the sedative activities of Cetirizine.Approved
ChloropyramineMethamphetamine may decrease the sedative activities of Chloropyramine.Approved
ChloroquineThe metabolism of Methamphetamine can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorphenamineMethamphetamine may decrease the sedative activities of Chlorphenamine.Approved
ChlorphenoxamineMethamphetamine may decrease the sedative activities of Chlorphenoxamine.Withdrawn
ChlorphentermineThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Methamphetamine.Illicit, Withdrawn
ChlorproethazineChlorproethazine may decrease the stimulatory activities of Methamphetamine.Experimental
ChlorpromazineThe metabolism of Methamphetamine can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneChlorprothixene may decrease the stimulatory activities of Methamphetamine.Approved, Withdrawn
CholecalciferolThe metabolism of Methamphetamine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe metabolism of Methamphetamine can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Methamphetamine can be decreased when combined with Cinacalcet.Approved
CinnarizineMethamphetamine may decrease the sedative activities of Cinnarizine.Approved
CitalopramThe metabolism of Methamphetamine can be decreased when combined with Citalopram.Approved
ClemastineThe metabolism of Methamphetamine can be decreased when combined with Clemastine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Clenbuterol is combined with Methamphetamine.Approved, Vet Approved
ClobazamThe metabolism of Methamphetamine can be decreased when combined with Clobazam.Approved, Illicit
ClomipramineClomipramine may decrease the antihypertensive activities of Methamphetamine.Approved, Vet Approved
ClopenthixolClopenthixol may decrease the stimulatory activities of Methamphetamine.Experimental
CloranololMethamphetamine may increase the atrioventricular blocking (AV block) activities of Cloranolol.Experimental
ClothiapineClothiapine may decrease the stimulatory activities of Methamphetamine.Experimental
ClotrimazoleThe metabolism of Methamphetamine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Methamphetamine can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Methamphetamine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Methamphetamine can be decreased when combined with Cocaine.Approved, Illicit
CodeineMethamphetamine may increase the analgesic activities of Codeine.Approved, Illicit
CyamemazineCyamemazine may decrease the stimulatory activities of Methamphetamine.Approved
CyclizineMethamphetamine may decrease the sedative activities of Cyclizine.Approved
CyclobenzaprineCyclobenzaprine may decrease the antihypertensive activities of Methamphetamine.Approved
CyproheptadineMethamphetamine may decrease the sedative activities of Cyproheptadine.Approved
DapiprazoleDapiprazole may decrease the stimulatory activities of Methamphetamine.Approved
DarifenacinThe metabolism of Methamphetamine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Methamphetamine can be increased when it is combined with Darunavir.Approved
DelavirdineThe metabolism of Methamphetamine can be decreased when combined with Delavirdine.Approved
DesipramineDesipramine may decrease the antihypertensive activities of Methamphetamine.Approved
DesloratadineMethamphetamine may decrease the sedative activities of Desloratadine.Approved, Investigational
DesvenlafaxineDesvenlafaxine may decrease the antihypertensive activities of Methamphetamine.Approved
DexbrompheniramineMethamphetamine may decrease the sedative activities of Dexbrompheniramine.Approved
DexchlorpheniramineMethamphetamine may decrease the sedative activities of Dexchlorpheniramine.Experimental
Dexchlorpheniramine maleateMethamphetamine may decrease the sedative activities of Dexchlorpheniramine maleate.Approved
DextromoramideMethamphetamine may increase the analgesic activities of Dextromoramide.Experimental, Illicit
DextropropoxypheneMethamphetamine may increase the analgesic activities of Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineMethamphetamine may increase the analgesic activities of Dezocine.Approved
DibenzepinDibenzepin may decrease the antihypertensive activities of Methamphetamine.Experimental
DiclofenamideDiclofenamide may decrease the excretion rate of Methamphetamine which could result in a higher serum level.Approved
DihydrocodeineMethamphetamine may increase the analgesic activities of Dihydrocodeine.Approved, Illicit
DihydroetorphineMethamphetamine may increase the analgesic activities of Dihydroetorphine.Experimental, Illicit
DihydromorphineMethamphetamine may increase the analgesic activities of Dihydromorphine.Experimental, Illicit
DimenhydrinateMethamphetamine may decrease the sedative activities of Dimenhydrinate.Approved
DimetindeneMethamphetamine may decrease the sedative activities of Dimetindene.Approved
DimetotiazineMethamphetamine may decrease the sedative activities of Dimetotiazine.Approved
DiphenhydramineThe metabolism of Methamphetamine can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateMethamphetamine may increase the analgesic activities of Diphenoxylate.Approved, Illicit
DixyrazineDixyrazine may decrease the stimulatory activities of Methamphetamine.Experimental
DobutamineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Methamphetamine.Approved
DopamineThe risk or severity of adverse effects can be increased when Dopamine is combined with Methamphetamine.Approved
DosulepinDosulepin may decrease the antihypertensive activities of Methamphetamine.Approved
DoxepinDoxepin may decrease the antihypertensive activities of Methamphetamine.Approved
DoxofyllineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Doxofylline.Approved
DoxylamineMethamphetamine may decrease the sedative activities of Doxylamine.Approved, Vet Approved
DPDPEMethamphetamine may increase the analgesic activities of DPDPE.Investigational
DronabinolDronabinol may increase the tachycardic activities of Methamphetamine.Approved, Illicit
DronedaroneThe metabolism of Methamphetamine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may decrease the stimulatory activities of Methamphetamine.Approved, Vet Approved
DuloxetineThe metabolism of Methamphetamine can be decreased when combined with Duloxetine.Approved
EbastineMethamphetamine may decrease the sedative activities of Ebastine.Investigational
EcopipamEcopipam may decrease the stimulatory activities of Methamphetamine.Investigational
EliglustatThe metabolism of Methamphetamine can be decreased when combined with Eliglustat.Approved
EmedastineMethamphetamine may decrease the sedative activities of Emedastine.Approved
EpanololMethamphetamine may increase the atrioventricular blocking (AV block) activities of Epanolol.Experimental
EphedrineThe risk or severity of adverse effects can be increased when Ephedrine is combined with Methamphetamine.Approved
EpinastineMethamphetamine may decrease the sedative activities of Epinastine.Approved, Investigational
EpinephrineThe risk or severity of adverse effects can be increased when Epinephrine is combined with Methamphetamine.Approved, Vet Approved
EsmirtazapineEsmirtazapine may decrease the antihypertensive activities of Methamphetamine.Investigational
EsmololMethamphetamine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
EthopropazineMethamphetamine may decrease the sedative activities of Ethopropazine.Approved
EthosuximideThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Methamphetamine.Approved
EthoxzolamideEthoxzolamide may decrease the excretion rate of Methamphetamine which could result in a higher serum level.Withdrawn
EthylmorphineMethamphetamine may increase the analgesic activities of Ethylmorphine.Approved, Illicit
EtilefrineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Etilefrine.Withdrawn
EtorphineMethamphetamine may increase the analgesic activities of Etorphine.Illicit, Vet Approved
FamotidineMethamphetamine may decrease the sedative activities of Famotidine.Approved
FencamfamineFencamfamine may decrease the stimulatory activities of Methamphetamine.Approved, Illicit, Withdrawn
FenoterolThe risk or severity of adverse effects can be increased when Fenoterol is combined with Methamphetamine.Approved
FenozoloneThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Fenozolone.Experimental
FentanylMethamphetamine may increase the analgesic activities of Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methamphetamine.Approved
FexofenadineMethamphetamine may decrease the sedative activities of Fexofenadine.Approved
FluanisoneFluanisone may decrease the stimulatory activities of Methamphetamine.Experimental
FlunarizineMethamphetamine may decrease the sedative activities of Flunarizine.Approved
FluoxetineThe metabolism of Methamphetamine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolFlupentixol may decrease the stimulatory activities of Methamphetamine.Approved, Withdrawn
FluphenazineFluphenazine may decrease the stimulatory activities of Methamphetamine.Approved
FluspirileneFluspirilene may decrease the stimulatory activities of Methamphetamine.Approved
FluvoxamineThe metabolism of Methamphetamine can be decreased when combined with Fluvoxamine.Approved, Investigational
FurazolidoneFurazolidone may increase the hypertensive activities of Methamphetamine.Approved, Vet Approved
Glutamic AcidThe serum concentration of Methamphetamine can be decreased when it is combined with Glutamic Acid.Approved, Nutraceutical
GuanethidineThe serum concentration of Methamphetamine can be decreased when it is combined with Guanethidine.Approved
HaloperidolThe metabolism of Methamphetamine can be decreased when combined with Haloperidol.Approved
HarmalineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Harmaline.Experimental
HeroinMethamphetamine may increase the analgesic activities of Heroin.Approved, Illicit
HydracarbazineHydracarbazine may increase the hypertensive activities of Methamphetamine.Experimental
HydrocodoneMethamphetamine may increase the analgesic activities of Hydrocodone.Approved, Illicit
HydromorphoneMethamphetamine may increase the analgesic activities of Hydromorphone.Approved, Illicit
HydrotalciteHydrotalcite may decrease the excretion rate of Methamphetamine which could result in a higher serum level.Experimental
HydroxyamphetamineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Hydroxyamphetamine.Approved
HydroxyzineMethamphetamine may decrease the sedative activities of Hydroxyzine.Approved
IloperidoneIloperidone may decrease the stimulatory activities of Methamphetamine.Approved
ImipramineImipramine may decrease the antihypertensive activities of Methamphetamine.Approved
IndenololMethamphetamine may increase the atrioventricular blocking (AV block) activities of Indenolol.Withdrawn
IndinavirThe metabolism of Methamphetamine can be decreased when combined with Indinavir.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Methamphetamine.Approved
Ioflupane I-123Methamphetamine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
IprindoleIprindole may decrease the antihypertensive activities of Methamphetamine.Experimental
IproclozideIproclozide may increase the hypertensive activities of Methamphetamine.Withdrawn
IproniazidIproniazid may increase the hypertensive activities of Methamphetamine.Withdrawn
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Methamphetamine.Approved
IsoniazidThe metabolism of Methamphetamine can be decreased when combined with Isoniazid.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Isoprenaline is combined with Methamphetamine.Approved
IsothipendylMethamphetamine may decrease the sedative activities of Isothipendyl.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Isoxsuprine.Approved, Withdrawn
KetobemidoneMethamphetamine may increase the analgesic activities of Ketobemidone.Approved
KetoconazoleThe metabolism of Methamphetamine can be decreased when combined with Ketoconazole.Approved, Investigational
KetotifenMethamphetamine may decrease the sedative activities of Ketotifen.Approved
LabetalolMethamphetamine may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved
LafutidineMethamphetamine may decrease the sedative activities of Lafutidine.Investigational
LandiololMethamphetamine may increase the atrioventricular blocking (AV block) activities of Landiolol.Investigational
LavoltidineMethamphetamine may decrease the sedative activities of Lavoltidine.Investigational
LevocabastineMethamphetamine may decrease the sedative activities of Levocabastine.Approved
LevocetirizineMethamphetamine may decrease the sedative activities of Levocetirizine.Approved
Levomethadyl AcetateMethamphetamine may increase the analgesic activities of Levomethadyl Acetate.Approved
LevomilnacipranLevomilnacipran may decrease the antihypertensive activities of Methamphetamine.Approved
LevorphanolMethamphetamine may increase the analgesic activities of Levorphanol.Approved
LinezolidLinezolid may increase the hypertensive activities of Methamphetamine.Approved, Investigational
LithiumLithium may decrease the stimulatory activities of Methamphetamine.Approved
LodoxamideMethamphetamine may decrease the sedative activities of Lodoxamide.Approved
LofentanilMethamphetamine may increase the analgesic activities of Lofentanil.Illicit
LofepramineLofepramine may decrease the antihypertensive activities of Methamphetamine.Experimental
LopinavirThe metabolism of Methamphetamine can be decreased when combined with Lopinavir.Approved
LoratadineMethamphetamine may decrease the sedative activities of Loratadine.Approved
LorcaserinThe metabolism of Methamphetamine can be decreased when combined with Lorcaserin.Approved
LoxapineLoxapine may decrease the stimulatory activities of Methamphetamine.Approved
LumefantrineThe metabolism of Methamphetamine can be decreased when combined with Lumefantrine.Approved
LurasidoneLurasidone may decrease the stimulatory activities of Methamphetamine.Approved
MagaldrateMagaldrate may decrease the excretion rate of Methamphetamine which could result in a higher serum level.Withdrawn
Magnesium HydroxideMagnesium Hydroxide may decrease the excretion rate of Methamphetamine which could result in a higher serum level.Approved
Magnesium oxideMagnesium oxide may decrease the excretion rate of Methamphetamine which could result in a higher serum level.Approved
Magnesium peroxideMagnesium peroxide may decrease the excretion rate of Methamphetamine which could result in a higher serum level.Experimental
Magnesium silicateMagnesium silicate may decrease the excretion rate of Methamphetamine which could result in a higher serum level.Experimental
Magnesium TrisilicateMagnesium Trisilicate may decrease the excretion rate of Methamphetamine which could result in a higher serum level.Approved
ManidipineThe metabolism of Methamphetamine can be decreased when combined with Manidipine.Approved
MebanazineMebanazine may increase the hypertensive activities of Methamphetamine.Withdrawn
MeclizineMethamphetamine may decrease the sedative activities of Meclizine.Approved
MefenorexThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Mefenorex.Experimental
MelperoneMelperone may decrease the stimulatory activities of Methamphetamine.Approved
MephentermineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Methamphetamine.Approved
MepindololMethamphetamine may increase the atrioventricular blocking (AV block) activities of Mepindolol.Experimental
MeptazinolMethamphetamine may increase the analgesic activities of Meptazinol.Experimental
MepyramineMethamphetamine may decrease the sedative activities of Mepyramine.Approved, Vet Approved
MequitazineMethamphetamine may decrease the sedative activities of Mequitazine.Approved
MesoridazineMesoridazine may decrease the stimulatory activities of Methamphetamine.Approved
MetaraminolThe risk or severity of adverse effects can be increased when Metaraminol is combined with Methamphetamine.Approved, Investigational
MethadoneThe metabolism of Methamphetamine can be decreased when combined with Methadone.Approved
Methadyl AcetateMethamphetamine may increase the analgesic activities of Methadyl Acetate.Approved, Illicit
MethapyrileneMethamphetamine may decrease the sedative activities of Methapyrilene.Withdrawn
MethazolamideMethazolamide may decrease the excretion rate of Methamphetamine which could result in a higher serum level.Approved
MethenamineThe serum concentration of Methamphetamine can be decreased when it is combined with Methenamine.Approved, Vet Approved
MethotrimeprazineThe metabolism of Methamphetamine can be decreased when combined with Methotrimeprazine.Approved
MethoxamineThe risk or severity of adverse effects can be increased when Methoxamine is combined with Methamphetamine.Approved
Methylene blueMethylene blue may increase the hypertensive activities of Methamphetamine.Investigational
MetiamideMethamphetamine may decrease the sedative activities of Metiamide.Experimental
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Methamphetamine.Approved, Investigational
MianserinThe therapeutic efficacy of Methamphetamine can be decreased when used in combination with Mianserin.Approved
MidodrineThe risk or severity of adverse effects can be increased when Midodrine is combined with Methamphetamine.Approved
MidostaurinThe metabolism of Methamphetamine can be decreased when combined with Midostaurin.Approved
MilnacipranMilnacipran may decrease the antihypertensive activities of Methamphetamine.Approved
MinaprineMinaprine may increase the hypertensive activities of Methamphetamine.Approved
MirabegronThe metabolism of Methamphetamine can be decreased when combined with Mirabegron.Approved
MirtazapineMirtazapine may decrease the antihypertensive activities of Methamphetamine.Approved
MizolastineMethamphetamine may decrease the sedative activities of Mizolastine.Investigational
MoclobemideMoclobemide may increase the hypertensive activities of Methamphetamine.Approved
MolindoneMolindone may decrease the stimulatory activities of Methamphetamine.Approved
MoperoneMoperone may decrease the stimulatory activities of Methamphetamine.Experimental
MorphineMethamphetamine may increase the analgesic activities of Morphine.Approved, Investigational
MosapramineMosapramine may decrease the stimulatory activities of Methamphetamine.Experimental
NabiloneNabilone may increase the tachycardic activities of Methamphetamine.Approved, Investigational
NadololMethamphetamine may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
NalbuphineMethamphetamine may increase the analgesic activities of Nalbuphine.Approved
NevirapineThe metabolism of Methamphetamine can be decreased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypertensive activities of Methamphetamine.Withdrawn
NicardipineThe metabolism of Methamphetamine can be decreased when combined with Nicardipine.Approved
NicomorphineMethamphetamine may increase the analgesic activities of Nicomorphine.Experimental
NilotinibThe metabolism of Methamphetamine can be decreased when combined with Nilotinib.Approved, Investigational
NizatidineMethamphetamine may decrease the sedative activities of Nizatidine.Approved
NorepinephrineThe risk or severity of adverse effects can be increased when Norepinephrine is combined with Methamphetamine.Approved
NormethadoneMethamphetamine may increase the analgesic activities of Normethadone.Approved, Illicit
NortriptylineNortriptyline may decrease the antihypertensive activities of Methamphetamine.Approved
NylidrinThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Nylidrin.Approved
OctamoxinOctamoxin may increase the hypertensive activities of Methamphetamine.Withdrawn
OlanzapineOlanzapine may decrease the stimulatory activities of Methamphetamine.Approved, Investigational
OlopatadineMethamphetamine may decrease the sedative activities of Olopatadine.Approved
OndansetronOndansetron may decrease the stimulatory activities of Methamphetamine.Approved
OpipramolOpipramol may decrease the antihypertensive activities of Methamphetamine.Investigational
OpiumMethamphetamine may increase the analgesic activities of Opium.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Orciprenaline is combined with Methamphetamine.Approved
OsanetantOsanetant may decrease the stimulatory activities of Methamphetamine.Investigational
OxatomideMethamphetamine may decrease the sedative activities of Oxatomide.Investigational
OxprenololMethamphetamine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved
OxycodoneMethamphetamine may increase the analgesic activities of Oxycodone.Approved, Illicit, Investigational
OxymetazolineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Methamphetamine.Approved
OxymorphoneMethamphetamine may increase the analgesic activities of Oxymorphone.Approved, Investigational, Vet Approved
OxypertineOxypertine may decrease the stimulatory activities of Methamphetamine.Experimental
OzagrelMethamphetamine may decrease the sedative activities of Ozagrel.Investigational
PaliperidonePaliperidone may decrease the stimulatory activities of Methamphetamine.Approved
PanobinostatThe serum concentration of Methamphetamine can be increased when it is combined with Panobinostat.Approved, Investigational
PargylinePargyline may increase the hypertensive activities of Methamphetamine.Approved
ParoxetineThe metabolism of Methamphetamine can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Methamphetamine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PemirolastMethamphetamine may decrease the sedative activities of Pemirolast.Approved
PenbutololMethamphetamine may increase the atrioventricular blocking (AV block) activities of Penbutolol.Approved, Investigational
PenfluridolPenfluridol may decrease the stimulatory activities of Methamphetamine.Experimental
PentazocineMethamphetamine may increase the analgesic activities of Pentazocine.Approved, Vet Approved
PerazinePerazine may decrease the stimulatory activities of Methamphetamine.Investigational
PerospironePerospirone may decrease the stimulatory activities of Methamphetamine.Approved
PerphenazinePerphenazine may decrease the stimulatory activities of Methamphetamine.Approved
PethidineMethamphetamine may increase the analgesic activities of Pethidine.Approved
PhenazocineMethamphetamine may increase the analgesic activities of Phenazocine.Experimental
PhenelzinePhenelzine may increase the hypertensive activities of Methamphetamine.Approved
PhenindamineMethamphetamine may decrease the sedative activities of Phenindamine.Approved
PheniprazinePheniprazine may increase the hypertensive activities of Methamphetamine.Withdrawn
PheniramineMethamphetamine may decrease the sedative activities of Pheniramine.Approved
PhenmetrazineThe risk or severity of adverse effects can be increased when Phenmetrazine is combined with Methamphetamine.Approved, Illicit
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Methamphetamine.Approved
PhenoperidineMethamphetamine may increase the analgesic activities of Phenoperidine.Experimental
PhenoxypropazinePhenoxypropazine may increase the hypertensive activities of Methamphetamine.Withdrawn
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Methamphetamine.Approved, Illicit
PhenylephrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Methamphetamine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Methamphetamine.Approved, Vet Approved, Withdrawn
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Methamphetamine.Approved, Vet Approved
PimozidePimozide may decrease the stimulatory activities of Methamphetamine.Approved
PindololMethamphetamine may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved
PipamperonePipamperone may decrease the stimulatory activities of Methamphetamine.Approved
PipotiazinePipotiazine may decrease the stimulatory activities of Methamphetamine.Approved
PiritramideMethamphetamine may increase the analgesic activities of Piritramide.Investigational
PirlindolePirlindole may increase the hypertensive activities of Methamphetamine.Approved
PivhydrazinePivhydrazine may increase the hypertensive activities of Methamphetamine.Withdrawn
PractololMethamphetamine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
PrenalterolThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Prenalterol.Experimental
ProcaterolThe risk or severity of adverse effects can be increased when Procaterol is combined with Methamphetamine.Approved
ProchlorperazineProchlorperazine may decrease the stimulatory activities of Methamphetamine.Approved, Vet Approved
PromazineThe metabolism of Methamphetamine can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineMethamphetamine may decrease the sedative activities of Promethazine.Approved
PropericiazinePropericiazine may decrease the stimulatory activities of Methamphetamine.Approved
PropranololMethamphetamine may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Investigational
ProthipendylProthipendyl may decrease the stimulatory activities of Methamphetamine.Investigational
ProtriptylineProtriptyline may decrease the antihypertensive activities of Methamphetamine.Approved
PseudoephedrineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Pseudoephedrine.Approved
QuetiapineQuetiapine may decrease the stimulatory activities of Methamphetamine.Approved
QuifenadineMethamphetamine may decrease the sedative activities of Quifenadine.Experimental
QuinidineThe metabolism of Methamphetamine can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Methamphetamine can be decreased when combined with Quinine.Approved
RacepinephrineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Racepinephrine.Approved
RacloprideRaclopride may decrease the stimulatory activities of Methamphetamine.Investigational
RanitidineMethamphetamine may decrease the sedative activities of Ranitidine.Approved
RanolazineThe metabolism of Methamphetamine can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the hypertensive activities of Methamphetamine.Approved
RemifentanilMethamphetamine may increase the analgesic activities of Remifentanil.Approved
RemoxiprideRemoxipride may decrease the stimulatory activities of Methamphetamine.Approved, Withdrawn
ReserpineReserpine may decrease the stimulatory activities of Methamphetamine.Approved
RisperidoneRisperidone may decrease the stimulatory activities of Methamphetamine.Approved, Investigational
RitanserinRitanserin may decrease the stimulatory activities of Methamphetamine.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Ritodrine is combined with Methamphetamine.Approved
RitonavirThe metabolism of Methamphetamine can be decreased when combined with Ritonavir.Approved, Investigational
RolapitantThe metabolism of Methamphetamine can be decreased when combined with Rolapitant.Approved
RopiniroleThe metabolism of Methamphetamine can be decreased when combined with Ropinirole.Approved, Investigational
Roxatidine acetateMethamphetamine may decrease the sedative activities of Roxatidine acetate.Approved
SafrazineSafrazine may increase the hypertensive activities of Methamphetamine.Withdrawn
SelegilineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Selegiline.Approved, Investigational, Vet Approved
SertindoleSertindole may decrease the stimulatory activities of Methamphetamine.Approved, Withdrawn
SertralineThe metabolism of Methamphetamine can be decreased when combined with Sertraline.Approved
SotalolMethamphetamine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
StiripentolThe metabolism of Methamphetamine can be decreased when combined with Stiripentol.Approved
SufentanilMethamphetamine may increase the analgesic activities of Sufentanil.Approved, Investigational
SulpirideSulpiride may decrease the stimulatory activities of Methamphetamine.Approved
SultoprideSultopride may decrease the stimulatory activities of Methamphetamine.Experimental
SynephrineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Synephrine.Experimental
TalinololMethamphetamine may increase the atrioventricular blocking (AV block) activities of Talinolol.Investigational
TapentadolMethamphetamine may increase the analgesic activities of Tapentadol.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the hypertensive activities of Methamphetamine.Approved
TerbinafineThe metabolism of Methamphetamine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Methamphetamine.Approved
TerfenadineMethamphetamine may decrease the sedative activities of Terfenadine.Withdrawn
TertatololMethamphetamine may increase the atrioventricular blocking (AV block) activities of Tertatolol.Experimental
TesmilifeneMethamphetamine may decrease the sedative activities of Tesmilifene.Investigational
TetrahydropalmatineTetrahydropalmatine may decrease the stimulatory activities of Methamphetamine.Investigational
TetryzolineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Tetryzoline.Approved
ThiopropazateThiopropazate may decrease the stimulatory activities of Methamphetamine.Experimental
ThioproperazineThioproperazine may decrease the stimulatory activities of Methamphetamine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Methamphetamine.Withdrawn
ThiothixeneThiothixene may decrease the stimulatory activities of Methamphetamine.Approved
ThonzylamineMethamphetamine may decrease the sedative activities of Thonzylamine.Approved
TianeptineTianeptine may decrease the antihypertensive activities of Methamphetamine.Approved
TiaprideTiapride may decrease the stimulatory activities of Methamphetamine.Approved, Investigational
TiclopidineThe metabolism of Methamphetamine can be decreased when combined with Ticlopidine.Approved
TilidineMethamphetamine may increase the analgesic activities of Tilidine.Experimental
TimololMethamphetamine may increase the atrioventricular blocking (AV block) activities of Timolol.Approved
TipranavirThe metabolism of Methamphetamine can be decreased when combined with Tipranavir.Approved, Investigational
ToloxatoneToloxatone may increase the hypertensive activities of Methamphetamine.Approved
TramadolMethamphetamine may increase the analgesic activities of Tramadol.Approved, Investigational
TramazolineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Tramazoline.Investigational
TranilastMethamphetamine may decrease the sedative activities of Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Methamphetamine.Experimental
TranylcypromineThe metabolism of Methamphetamine can be decreased when combined with Tranylcypromine.Approved
TretoquinolThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Tretoquinol.Experimental
TrifluoperazineTrifluoperazine may decrease the stimulatory activities of Methamphetamine.Approved
TrifluperidolTrifluperidol may decrease the stimulatory activities of Methamphetamine.Experimental
TriflupromazineTriflupromazine may decrease the stimulatory activities of Methamphetamine.Approved, Vet Approved
TrimipramineTrimipramine may decrease the antihypertensive activities of Methamphetamine.Approved
TripelennamineMethamphetamine may decrease the sedative activities of Tripelennamine.Approved, Vet Approved
TriprolidineMethamphetamine may decrease the sedative activities of Triprolidine.Approved
TritoqualineMethamphetamine may decrease the sedative activities of Tritoqualine.Experimental
TyramineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Tyramine.Investigational, Nutraceutical
VenlafaxineThe metabolism of Methamphetamine can be decreased when combined with Venlafaxine.Approved
VeraliprideVeralipride may decrease the stimulatory activities of Methamphetamine.Experimental
Vitamin CThe serum concentration of Methamphetamine can be decreased when it is combined with Vitamin C.Approved, Nutraceutical
ZiprasidoneThe metabolism of Methamphetamine can be decreased when combined with Ziprasidone.Approved
ZotepineZotepine may decrease the stimulatory activities of Methamphetamine.Approved
ZuclopenthixolZuclopenthixol may decrease the stimulatory activities of Methamphetamine.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Nobuyuki Shigetoh, Hiroshi Nakayama, Jinsei Miyazaki, Tadayasu Mitsumata, "Labelling colors for detecting cocaine or methamphetamine, method of preparing the same and detector for cocaine or methamphetamine." U.S. Patent US5571727, issued October, 1981.

US5571727
General References
  1. Schepers RJ, Oyler JM, Joseph RE Jr, Cone EJ, Moolchan ET, Huestis MA: Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. Clin Chem. 2003 Jan;49(1):121-32. [PubMed:12507968]
  2. McGregor C, Srisurapanont M, Jittiwutikarn J, Laobhripatr S, Wongtan T, White JM: The nature, time course and severity of methamphetamine withdrawal. Addiction. 2005 Sep;100(9):1320-9. [PubMed:16128721]
  3. Bennett BA, Hollingsworth CK, Martin RS, Harp JJ: Methamphetamine-induced alterations in dopamine transporter function. Brain Res. 1998 Jan 26;782(1-2):219-27. [PubMed:9519266]
  4. Hasan AA, Ciancio S: Relationship between amphetamine ingestion and gingival enlargement. Pediatr Dent. 2004 Sep-Oct;26(5):396-400. [PubMed:15460293]
  5. Shaner JW: Caries associated with methamphetamine abuse. J Mich Dent Assoc. 2002 Sep;84(9):42-7. [PubMed:12271905]
External Links
Human Metabolome Database
HMDB15517
KEGG Compound
C07164
PubChem Compound
10836
PubChem Substance
46508541
ChemSpider
10379
BindingDB
50359499
ChEBI
6809
ChEMBL
CHEMBL1201201
Therapeutic Targets Database
DAP001496
PharmGKB
PA450403
HET
B40
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Methamphetamine
ATC Codes
N06BA03 — Metamfetamine
PDB Entries
3gkz / 4gqp / 4xp6
FDA label
Download (55.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedHealth Services ResearchMethamphetamine Dependence1
0RecruitingBasic ScienceMethamphetamine Abuse / Methamphetamine Dependence1
1CompletedBasic ScienceMethamphetamine Abuse / Methamphetamine Dependence1
1Not Yet RecruitingTreatmentMethamphetamine Use Disorder1
2RecruitingBasic ScienceMethamphetamine Abuse / Substance Use Disorder (SUD)1
4Active Not RecruitingOtherSubstance-Related Disorders1
Not AvailableCompletedBasic ScienceSubstance Abuse1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
TabletOral5 mg/1
Prices
Unit descriptionCostUnit
Desoxyn 5 mg tablet5.1USD tablet
Methamphetamine 5 mg tablet3.6USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP2.07HANSCH,C ET AL. (1995)
pKa9.87 (at 25 °C)PERRIN,DD (1965)
Predicted Properties
PropertyValueSource
Water Solubility0.928 mg/mLALOGPS
logP2.23ALOGPS
logP2.24ChemAxon
logS-2.2ALOGPS
pKa (Strongest Basic)10.21ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area12.03 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity48.48 m3·mol-1ChemAxon
Polarizability18.04 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.993
Blood Brain Barrier+0.9695
Caco-2 permeable+0.8675
P-glycoprotein substrateNon-substrate0.6682
P-glycoprotein inhibitor INon-inhibitor0.9338
P-glycoprotein inhibitor IINon-inhibitor0.9816
Renal organic cation transporterNon-inhibitor0.736
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateNon-substrate0.7
CYP450 1A2 substrateNon-inhibitor0.6771
CYP450 2C9 inhibitorNon-inhibitor0.957
CYP450 2D6 inhibitorInhibitor0.8695
CYP450 2C19 inhibitorNon-inhibitor0.7754
CYP450 3A4 inhibitorNon-inhibitor0.9536
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9095
Ames testNon AMES toxic0.9306
CarcinogenicityNon-carcinogens0.8161
BiodegradationNot ready biodegradable0.7508
Rat acute toxicity3.1862 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9443
hERG inhibition (predictor II)Non-inhibitor0.9118
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (2.96 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-0a4i-9000000000-fd0454cafd58d60de713
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0gb9-2900000000-9f47787fb23e13a87dad
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0900000000-7337ca7928cea10bffe5
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udl-5900000000-03d47250c7a980a66e20
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-9300000000-d10984417cc7279a776b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-9000000000-ba626750e38f88879a89
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-9000000000-3e56ce6f6bf92f4b0a14
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-9000000000-4095966beeb0165843c9
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0900000000-7337ca7928cea10bffe5
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udl-5900000000-bb1f4cbf0ac7cca4d691
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-9300000000-6e88a7d0ffb252a513da
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-9000000000-70ddbc2127d9ecc43ec0
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-9000000000-faa0136ac65ec9065e49
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-9000000000-ce6e9f98d322c724f026
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0gb9-2900000000-753b4591b9e358e01e68
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00kf-9800000000-94af1bb67acf7028de89
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00kf-9800000000-904b385cb2c1370393d6
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-9200000000-49618d55cba0c2470ba6
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-9000000000-3167ad4af9af7ec20657
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-9000000000-351c5861a20ce31f40a9
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-9000000000-cd1055202e84beaff361

Taxonomy

Description
This compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenethylamines
Direct Parent
Amphetamines and derivatives
Alternative Parents
Phenylpropanes / Aralkylamines / Dialkylamines / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Amphetamine or derivatives / Phenylpropane / Aralkylamine / Secondary amine / Secondary aliphatic amine / Organic nitrogen compound / Organopnictogen compound / Hydrocarbon derivative / Organonitrogen compound / Amine
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
amphetamines (CHEBI:6809)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Negative modulator
General Function
Monoamine transmembrane transporter activity
Specific Function
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A3
Uniprot ID
Q01959
Uniprot Name
Sodium-dependent dopamine transporter
Molecular Weight
68494.255 Da
References
  1. Escubedo E, Camarasa J, Chipana C, Garcia-Rates S, Pubill D: Involvement of nicotinic receptors in methamphetamine- and MDMA-induced neurotoxicity: pharmacological implications. Int Rev Neurobiol. 2009;88:121-66. doi: 10.1016/S0074-7742(09)88006-9. [PubMed:19897077]
  2. Lott DC, Kim SJ, Cook EH Jr, de Wit H: Dopamine transporter gene associated with diminished subjective response to amphetamine. Neuropsychopharmacology. 2005 Mar;30(3):602-9. [PubMed:15602501]
  3. Fone KC, Nutt DJ: Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder. Curr Opin Pharmacol. 2005 Feb;5(1):87-93. [PubMed:15661631]
  4. Miller GM, Verrico CD, Jassen A, Konar M, Yang H, Panas H, Bahn M, Johnson R, Madras BK: Primate trace amine receptor 1 modulation by the dopamine transporter. J Pharmacol Exp Ther. 2005 Jun;313(3):983-94. Epub 2005 Mar 11. [PubMed:15764732]
  5. Garcia BG, Wei Y, Moron JA, Lin RZ, Javitch JA, Galli A: Akt is essential for insulin modulation of amphetamine-induced human dopamine transporter cell-surface redistribution. Mol Pharmacol. 2005 Jul;68(1):102-9. Epub 2005 Mar 28. [PubMed:15795321]
  6. Madras BK, Miller GM, Fischman AJ: The dopamine transporter and attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005 Jun 1;57(11):1397-409. Epub 2005 Jan 5. [PubMed:15950014]
  7. Kahlig KM, Binda F, Khoshbouei H, Blakely RD, McMahon DG, Javitch JA, Galli A: Amphetamine induces dopamine efflux through a dopamine transporter channel. Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3495-500. Epub 2005 Feb 22. [PubMed:15728379]
  8. Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR: New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol. 2007;47:681-98. [PubMed:17209801]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Negative modulator
General Function
Serotonin:sodium symporter activity
Specific Function
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
Gene Name
SLC6A4
Uniprot ID
P31645
Uniprot Name
Sodium-dependent serotonin transporter
Molecular Weight
70324.165 Da
References
  1. Numachi Y, Ohara A, Yamashita M, Fukushima S, Kobayashi H, Hata H, Watanabe H, Hall FS, Lesch KP, Murphy DL, Uhl GR, Sora I: Methamphetamine-induced hyperthermia and lethal toxicity: role of the dopamine and serotonin transporters. Eur J Pharmacol. 2007 Oct 31;572(2-3):120-8. Epub 2007 Jun 27. [PubMed:17673199]
  2. Tellez R, Rocha L, Castillo C, Meneses A: Autoradiographic study of serotonin transporter during memory formation. Behav Brain Res. 2010 Sep 1;212(1):12-26. doi: 10.1016/j.bbr.2010.03.015. Epub 2010 Mar 11. [PubMed:20226815]
  3. Sora I, Li B, Fumushima S, Fukui A, Arime Y, Kasahara Y, Tomita H, Ikeda K: Monoamine transporter as a target molecule for psychostimulants. Int Rev Neurobiol. 2009;85:29-33. doi: 10.1016/S0074-7742(09)85003-4. [PubMed:19607959]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Negative modulator
General Function
Norepinephrine:sodium symporter activity
Specific Function
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A2
Uniprot ID
P23975
Uniprot Name
Sodium-dependent noradrenaline transporter
Molecular Weight
69331.42 Da
References
  1. Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR: New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol. 2007;47:681-98. [PubMed:17209801]
  2. Sulzer D, Sonders MS, Poulsen NW, Galli A: Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol. 2005 Apr;75(6):406-33. [PubMed:15955613]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Monoamine transmembrane transporter activity
Specific Function
Involved in the ATP-dependent vesicular transport of biogenic amine neurotransmitters. Pumps cytosolic monoamines including dopamine, norepinephrine, serotonin, and histamine into synaptic vesicles...
Gene Name
SLC18A2
Uniprot ID
Q05940
Uniprot Name
Synaptic vesicular amine transporter
Molecular Weight
55712.075 Da
References
  1. Horton DB, Siripurapu KB, Norrholm SD, Culver JP, Hojahmat M, Beckmann JS, Harrod SB, Deaciuc AG, Bardo MT, Crooks PA, Dwoskin LP: meso-Transdiene analogs inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release. J Pharmacol Exp Ther. 2011 Mar;336(3):940-51. doi: 10.1124/jpet.110.175117. Epub 2010 Dec 21. [PubMed:21177475]
  2. Sulzer D, Sonders MS, Poulsen NW, Galli A: Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol. 2005 Apr;75(6):406-33. [PubMed:15955613]
  3. Sulzer D, Chen TK, Lau YY, Kristensen H, Rayport S, Ewing A: Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J Neurosci. 1995 May;15(5 Pt 2):4102-8. [PubMed:7751968]
  4. Yasumoto S, Tamura K, Karasawa J, Hasegawa R, Ikeda K, Yamamoto T, Yamamoto H: Inhibitory effect of selective serotonin reuptake inhibitors on the vesicular monoamine transporter 2. Neurosci Lett. 2009 May 1;454(3):229-32. doi: 10.1016/j.neulet.2009.03.049. Epub 2009 Mar 18. [PubMed:19429089]
  5. Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR: New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol. 2007;47:681-98. [PubMed:17209801]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serotonin transmembrane transporter activity
Specific Function
Involved in the transport of biogenic monoamines, such as serotonin, from the cytoplasm into the secretory vesicles of neuroendocrine and endocrine cells.
Gene Name
SLC18A1
Uniprot ID
P54219
Uniprot Name
Chromaffin granule amine transporter
Molecular Weight
56256.71 Da
References
  1. Sulzer D, Sonders MS, Poulsen NW, Galli A: Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol. 2005 Apr;75(6):406-33. [PubMed:15955613]
  2. Henry JP, Sagne C, Bedet C, Gasnier B: The vesicular monoamine transporter: from chromaffin granule to brain. Neurochem Int. 1998 Mar;32(3):227-46. [PubMed:9587917]
  3. Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR: New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol. 2007;47:681-98. [PubMed:17209801]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Trace-amine receptor activity
Specific Function
Receptor for trace amines, including beta-phenylethylamine (b-PEA), p-tyramine (p-TYR), octopamine and tryptamine, with highest affinity for b-PEA and p-TYR. Unresponsive to classical biogenic amin...
Gene Name
TAAR1
Uniprot ID
Q96RJ0
Uniprot Name
Trace amine-associated receptor 1
Molecular Weight
39091.34 Da
References
  1. Grandy DK: Trace amine-associated receptor 1-Family archetype or iconoclast? Pharmacol Ther. 2007 Dec;116(3):355-90. Epub 2007 Jul 17. [PubMed:17888514]
  2. Borowsky B, Adham N, Jones KA, Raddatz R, Artymyshyn R, Ogozalek KL, Durkin MM, Lakhlani PP, Bonini JA, Pathirana S, Boyle N, Pu X, Kouranova E, Lichtblau H, Ochoa FY, Branchek TA, Gerald C: Trace amines: identification of a family of mammalian G protein-coupled receptors. Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):8966-71. Epub 2001 Jul 17. [PubMed:11459929]
  3. Reese EA, Bunzow JR, Arttamangkul S, Sonders MS, Grandy DK: Trace amine-associated receptor 1 displays species-dependent stereoselectivity for isomers of methamphetamine, amphetamine, and para-hydroxyamphetamine. J Pharmacol Exp Ther. 2007 Apr;321(1):178-86. Epub 2007 Jan 11. [PubMed:17218486]
  4. Xie Z, Westmoreland SV, Bahn ME, Chen GL, Yang H, Vallender EJ, Yao WD, Madras BK, Miller GM: Rhesus monkey trace amine-associated receptor 1 signaling: enhancement by monoamine transporters and attenuation by the D2 autoreceptor in vitro. J Pharmacol Exp Ther. 2007 Apr;321(1):116-27. Epub 2007 Jan 18. [PubMed:17234900]
  5. Wolinsky TD, Swanson CJ, Smith KE, Zhong H, Borowsky B, Seeman P, Branchek T, Gerald CP: The Trace Amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia. Genes Brain Behav. 2007 Oct;6(7):628-39. Epub 2006 Dec 21. [PubMed:17212650]
  6. Xie Z, Miller GM: Trace amine-associated receptor 1 is a modulator of the dopamine transporter. J Pharmacol Exp Ther. 2007 Apr;321(1):128-36. Epub 2007 Jan 18. [PubMed:17234899]
  7. Miller GM, Verrico CD, Jassen A, Konar M, Yang H, Panas H, Bahn M, Johnson R, Madras BK: Primate trace amine receptor 1 modulation by the dopamine transporter. J Pharmacol Exp Ther. 2005 Jun;313(3):983-94. Epub 2005 Mar 11. [PubMed:15764732]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. Jeng CH, Wang Y: Methamphetamine modulates GABA-induced electrophysiological depression by alternating noradrenergic actions in cerebellar Purkinje neurons. Psychopharmacology (Berl). 1998 Mar;136(2):132-8. [PubMed:9551769]
  2. Sulzer D, Sonders MS, Poulsen NW, Galli A: Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol. 2005 Apr;75(6):406-33. [PubMed:15955613]
  3. Nishio M, Kanda Y, Mizuno K, Watanabe Y: Methamphetamine increases the hippocampal alpha(2A)-adrenergic receptor and Galpha(o) in mice. Neurosci Lett. 2002 Dec 16;334(3):145-8. [PubMed:12453616]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Epinephrine binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine...
Gene Name
ADRA2B
Uniprot ID
P18089
Uniprot Name
Alpha-2B adrenergic receptor
Molecular Weight
49565.8 Da
References
  1. Jeng CH, Wang Y: Methamphetamine modulates GABA-induced electrophysiological depression by alternating noradrenergic actions in cerebellar Purkinje neurons. Psychopharmacology (Berl). 1998 Mar;136(2):132-8. [PubMed:9551769]
  2. Sulzer D, Sonders MS, Poulsen NW, Galli A: Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol. 2005 Apr;75(6):406-33. [PubMed:15955613]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Protein homodimerization activity
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name
ADRA2C
Uniprot ID
P18825
Uniprot Name
Alpha-2C adrenergic receptor
Molecular Weight
49521.585 Da
References
  1. Jeng CH, Wang Y: Methamphetamine modulates GABA-induced electrophysiological depression by alternating noradrenergic actions in cerebellar Purkinje neurons. Psychopharmacology (Berl). 1998 Mar;136(2):132-8. [PubMed:9551769]
  2. Sulzer D, Sonders MS, Poulsen NW, Galli A: Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol. 2005 Apr;75(6):406-33. [PubMed:15955613]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serotonin binding
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOA
Uniprot ID
P21397
Uniprot Name
Amine oxidase [flavin-containing] A
Molecular Weight
59681.27 Da
References
  1. Sulzer D, Sonders MS, Poulsen NW, Galli A: Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol. 2005 Apr;75(6):406-33. [PubMed:15955613]
  2. Ulus IH, Maher TJ, Wurtman RJ: Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors. Biochem Pharmacol. 2000 Jun 15;59(12):1611-21. [PubMed:10799660]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Primary amine oxidase activity
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOB
Uniprot ID
P27338
Uniprot Name
Amine oxidase [flavin-containing] B
Molecular Weight
58762.475 Da
References
  1. Sulzer D, Sonders MS, Poulsen NW, Galli A: Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol. 2005 Apr;75(6):406-33. [PubMed:15955613]
  2. Ulus IH, Maher TJ, Wurtman RJ: Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors. Biochem Pharmacol. 2000 Jun 15;59(12):1611-21. [PubMed:10799660]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Toxin transporter activity
Specific Function
Mediates potential-dependent transport of a variety of organic cations. May play a significant role in the disposition of cationic neurotoxins and neurotransmitters in the brain.
Gene Name
SLC22A3
Uniprot ID
O75751
Uniprot Name
Solute carrier family 22 member 3
Molecular Weight
61279.485 Da
References
  1. Wu X, Kekuda R, Huang W, Fei YJ, Leibach FH, Chen J, Conway SJ, Ganapathy V: Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. J Biol Chem. 1998 Dec 4;273(49):32776-86. [PubMed:9830022]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Symporter activity
Specific Function
Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cat...
Gene Name
SLC22A5
Uniprot ID
O76082
Uniprot Name
Solute carrier family 22 member 5
Molecular Weight
62751.08 Da
References
  1. Wu X, Prasad PD, Leibach FH, Ganapathy V: cDNA sequence, transport function, and genomic organization of human OCTN2, a new member of the organic cation transporter family. Biochem Biophys Res Commun. 1998 May 29;246(3):589-95. [PubMed:9618255]
  2. Wu X, Huang W, Prasad PD, Seth P, Rajan DP, Leibach FH, Chen J, Conway SJ, Ganapathy V: Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter. J Pharmacol Exp Ther. 1999 Sep;290(3):1482-92. [PubMed:10454528]

Drug created on August 29, 2007 08:51 / Updated on October 02, 2017 05:00